Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
While initial therapies have become highly effective with introduction of lenalidomide and bortezomib and patients may opt for delayed stem cell transplantation, it is important to collect stem cells for future transplant. Given its increasing use as initial therapy, we examined if lenalidomide had any impact on the ability to collect peripheral blood stem cells (PBSC). We studied the entire cohort of patients with myeloma undergoing PBSC mobilization at our institution during a 5-year period, comparing the results between patients receiving different initial therapies. Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P<0.001), average daily collection (P<0.001), day 1 collection (P<0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD. A similar trend was seen in those mobilized with chemotherapy and G-CSF. A trend was seen towards decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age (P=0.002). There was no effect on quality of PBSC collected based on similar engraftment across all groups. We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.112”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [112]
In the citing paper
“This issue can often be overcome using high-dose cyclophosphamide or the CXCR4 antagonist plerixafor125.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [125]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · cited 1×
“dtd"[ ]> Introduction High-dose therapy and autologous stem cell transplantation has been an important part of myeloma therapy ever since the initial randomized trials demonstrated a survival benefit for the procedure compared to conventional chemotherapy”
BackgroundSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 1×
“11 Recent advances in the field, including the potential impact of tandem stem cell transplant and introduction of very effective agents such as bortezomib and lenalidomide have changed the landscape of treatment of myeloma”
BackgroundRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Self-citationCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citationProteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Self-citation
Cited by
Items 201–300 of 351
Stover, J. T., Shaw, J. R., Kuchibhatla, M. N., Horwitz, M. E., & Engemann, A. M. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.04.007 · Cited by 11
A Mixed-Methods Study of Stem Cell Transplantation Utilization for Newly Diagnosed Multiple Myeloma
Fiala, M. A., Vij, R., & Wildes, T. M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.05.003 · Cited by 13
Zubair, A. C., Rymer, R., Young, J., Keeton, U., Befort, R., Nolot, B., Evans, C., Bleach, T., & Torloni, A. S. (2009) · Journal of Clinical Apheresis · doi:10.1002/jca.20190 · Cited by 11
“Some heavily pretreated patients, particularly those who received thalidomide and or its derivatives (lenalidomide), undergo more than average number of collections to reach their target cell dose [7].”
Current Treatment Strategies with Lenalidomide in Multiple Myeloma and Future Perspectives
Larocca, A., Cavallo, F., Mina, R., Boccadoro, M., & Palumbo, A. P. (2012) · Future Oncology · doi:10.2217/fon.12.124 · Cited by 10
“Some reports have indicated that lenalidomide may reduce stem cell numbers, without harming the stem cells themselves, and that the duration of lenalidomide therapy may influence mobilization [35,36].”
BackgroundSamaras, P., Bargetzi, M. J., Betticher, D. C., Duchosal, M. A., Heim, D. A., Hess, U., Ketterer, N., Lerch, E., Matthes, T., Mey, U., et al. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14100 · Cited by 11
Sancho, J., Duarte, R. F., Medina, L. L. A., Querol, S., Marín, P., & Sureda, A. M. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.05.019 · Cited by 10
Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Laubach, J. P., & Kumar, S. K. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_9 · Cited by 10
Self-citationDrozd-Sokolowska, J. E., Waszczuk‐Gajda, A., Topczewska, M., Mańko, J., Hus, I., Szmigielska‐Kapłon, A., Nowicki, M., Grygoruk‐Wiśniowska, I., Krawczyk‐Kuliś, M., Romejko‐Jarosińska, J., et al. (2021) · Journal of Clinical Apheresis · doi:10.1002/jca.21885 · Cited by 10
Bringhen, S., Gay, F., Pautasso, C., Cerrato, C., Boccadoro, M., & Palumbo, A. P. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.712685 · Cited by 11
“Some reports indicated that lenalidomide may reduce stem cell harvest and that the duration of lenalidomide treatment may influence mobilization [89,90].”
BackgroundSidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J. S., Le, A., Muffly, L. S., Maysel-Auslender, S., Johnston, L., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01152-1 · Cited by 10
Self-citationFirst linevsdelayed transplantation in myeloma: Certainties and controversies
Brioli, A. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i2.321 · Cited by 11
Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients
Hsu, T.-L., Tsai, C., Liu, C., Yeh, C., Lin, F.-L., Hsiao, L., Liu, Y., Wang, H., Ko, P., Lin, T., et al. (2022) · Transfusion Medicine and Hemotherapy · doi:10.1159/000525565 · Cited by 10
Fang, F., Lan, X., Hu, R., Hui, W.-H., Zhao, H., Guo, Y., Ji, B., Liu, H., Su, L., & Sun, W. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231219151 · Cited by 9
Autologous Stem Cell Mobilization in the Age of Plerixafor
COOPER, D. L., Medoff, E., Patel, N. J., Baker, J., Pratt, K., Foss, F. M., Seropian, S., Perreault, S., & Wu, Y. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.04.007 · Cited by 9
Duan, H., Jiang, Q., Liu, L., Deng, M., Lai, Q., Jiang, Y., Li, Z., Xu, B., & Lin, Z. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05683-2 · Cited by 9
Ishii, A., Jo, T., Arai, Y., Oshima, S., Kanda, J., Kitawaki, T., Matsui, K., Niwa, N., Nakagawa, Y., Takaori‐Kondo, A., et al. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.09.004 · Cited by 9
“Furthermore, the effects of several factors other than PB-CD34, which have been reported to affect CD34 cell yield [7,9,10], have not been assessed quantitatively in previous studies.”
ResultHus, I., Mańko, J., Jawniak, D., Jurczyszyn, A. J., Charliński, G., Poniewierska‐Jasak, K., Usnarska‐Zubkiewicz, L., Sawicki, M., Druzd‐Sitek, A., Świderska, A., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10929 · Cited by 9
“In contrast, lenalidomide was reported to adversely impair HSC harvest (41-43), though in the more recent retrospective analysis a sufficient number of stem cells was obtained in MM patients treated with lenalidomide-based regimens (44).”
ResultSauer, S., Kriegsmann, K., Nientiedt, C., Schmitt, A., Müller‐Tidow, C., Raab, M., & Kauer, J. (2023) · Transfusion Medicine and Hemotherapy · doi:10.1159/000529691 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00104-1 · Cited by 10
Self-citationCosta, L. J., Kumar, S. K., Stowell, S. A., & Dermer, S. J. (2015) · Cancer Control · doi:10.1177/107327481502200111 · Cited by 8
“This proportion was even higher than the proportion of oncologists who avoided lenalidomide, a drug shown to impair mobilization.(23,24) More than one-half of health care professionals from both specialties acknowledged that lenalidomide can be used”
BackgroundSelf-citationJung, S., Park, H., Ahn, J., Yang, D., Kim, M., Kim, Y., Kim, H., & Lee, J. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1237-0 · Cited by 10
“negatively affected stem cell mobilization [8, 9].”
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00101-8 · Cited by 8
Self-citationJagirdar, N., Harvey, R. D., Nooka, A. K., Flowers, C. R., Kaufman, J. L., Lonial, S., Lechowicz, M. J., Langston, A. A., Lipscomb, C., Gaylor, C., et al. (2015) · Transfusion · doi:10.1111/trf.13186 · Cited by 8
Plerixafor for autologous CD34+ cell mobilization
Salman, H., & Lazarus, H. M. (2011) · Core evidence · doi:10.2147/ce.s7801 · Cited by 7
Mehl, J., Akhoundova, D., Bacher, U., Jeker, B., Agocs, G. R., Ruefer, A., Soltermann, S., Soekler, M., Winkler, A., Daskalakis, M., et al. (2024) · Cancers · doi:10.3390/cancers16101854 · Cited by 9
“Choice of induction regimen, number of administered cycles, stem cell mobilization regimen, use of plerixafor, and patient age were shown to impact CD34+ stem cell mobilization potential [18–26].”
BackgroundNovel agents in myeloma: An exciting saga
Mark, T. M., Niesvizky, R., & Coleman, M. (2008) · Cancer · doi:10.1002/cncr.24040 · Cited by 7
“By contrast, lenalidomide use beyond a period of 6 months has been shown to have a negative impact on the mobilization of stem cells and has led to collection failures, especially when the mobilization regimen consists of granulocyte colony-stimulating factor (GCSF) alone.(38,39) Our group confirmed this finding and h…”
BackgroundOld and new generation immunomodulatory drugs in multiple myeloma
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04125-7 · Cited by 8
Taenaka, R., Shimokawa, S., Katayama, A., Nagao, T., Obara, T., Nishimura, N., Tsujimoto, A., Kohno, K., Aoki, K., & Ogawa, R. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03552-y · Cited by 7
“In transplant-eligible patients with POEMS syndrome, there is concern that daratumumab and lenalidomide may cause poor mobilization of hematopoietic stem cells [8, 9].”
BackgroundPartanen, A., Turunen, A., Silvennoinen, R. H., Valtola, J., Pyörälä, M., Siitonen, T., Sikiö, A., Putkonen, M., Sankelo, M., Penttilä, K., et al. (2022) · Journal of Clinical Apheresis · doi:10.1002/jca.22022 · Cited by 7
Sauer, S., Hieke, L., Brandt, J., Müller‐Tidow, C., Schmitt, A., Kauer, J., & Kriegsmann, K. (2023) · Transfusion Medicine and Hemotherapy · doi:10.1159/000530056 · Cited by 7
Bittrich, M., Kriegsmann, K., Tietze-Stolley, C., Movassaghi, K., Grube, M., Vučinić, V., Wehler, D., Burchert, A., Schmidt‐Hieber, M., Rank, A., et al. (2023) · Transfusion Medicine and Hemotherapy · doi:10.1159/000531935 · Cited by 8
Doo, N. W., Coory, M. D., WHITE, V. M., Harrison, S. J., Prince, H. M., Millar, J. L., Dimech, M., & Giles, G. G. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.09.011 · Cited by 7
Olivier, P., Teisseyre, A.-C., & Montastruc, J. (2013) · Medical Oncology · doi:10.1007/s12032-013-0733-2 · Cited by 7
“The mechanism leading to myelotoxicity is not yet totally elucidated: a direct toxicity of lenalidomide has been proposed [24].”
BackgroundLenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Tuchman, S. A., Chao, N. J. A., & Gasparetto, C. (2012) · Advances in Hematology · doi:10.1155/2012/712613 · Cited by 7
“Despite impaired mobilization, however, no difference in engraftment kinetics was evident (denoting length of time until peripheral blood cell count recovery after reinfusion of stem cells) [19].”
BackgroundTanimura, A., Hirai, R., Nakamura, M., Takeshita, M., Hagiwara, S., & Miwa, A. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2408-4 · Cited by 9
“The incidence of harvest failure was reported to increase after induction therapies containing lenalidomide when PBSCH was attempted with the G-alone regimen [26].”
MethodMilone, G., Conticello, C., Leotta, S., Michieli, M., Martino, M. V., Marco, A. L. D., Spadaro, A., Cupri, A., Condorelli, A., Milone, G. A., et al. (2020) · Leukemia Research Reports · doi:10.1016/j.lrr.2020.100227 · Cited by 7
“Age [23], previous treatment with melphalan [24] or agents like lenalidomide [25] are clinical factors recognized as relevant for determining results of mobilization and apheretic harvest in MM.”
BackgroundVarga, C., Robinson, M. M., Gupta, V. A., Hofmeister, C. C., Nooka, A. K., Kaufman, J. L., Dhodapkar, M. V., Lonial, S., Borden, S., Ferreri, C. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.003 · Cited by 6
Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma
Kwon, S., Park, H. Y., Byun, J. M., Shin, D., Koh, Y., Hong, J., Kim, I., & Yoon, S. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06372-4 · Cited by 6
“Early stem cell collection is widely recognized as cru - cial for patients receiving VRD [15– 17 ].”
Kumar, R., Kapoor, R., Asthana, B., Singh, J., Verma, T., Rajesh, C., Singh, N., Sharma, A., Das, S., & Nair, V. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0798-8 · Cited by 6
“] Lenalidomide based initial therapy has been associated with increased risk of mobilization failure [27, 33, 34, 41].”
BackgroundRybinski, B., Rapoport, A. P., Badros, A. Z., Hardy, N. M., & Kocoglu, M. H. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.03.013 · Cited by 6
“Not evaluable/unknown: 4 (7) Not evaluable/unknown: 3 (8) Calcium d mg/dL, median (range, n) 9.”
InfluentialPlerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
Selleslag, D., Dierickx, D., Breems, D., Huynh, P., de Velde, A. V., Meers, S., Brouwer, E., & Mertens, A. C. (2011) · PubMed · doi:10.2143/acb.66.3.2062547 · Cited by 6
Kim, J. S., Yoon, D. H., Park, S., Yoon, S., Cho, S., Min, C., Lee, J., Yang, D., Kwak, J., Eom, H., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2589-y · Cited by 6
Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients
Sancho, J., Duarte, R. F., Medina, L. L. A., Querol, S., Marín, P., & Sureda, A. M. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.05.052 · Cited by 7
Kostroma, I. I., Zherniakova, A., Chubukina, Z. V., Запреева, И. М., Тиранова, С. А., Сельцер, А. В., Semenova, N. Y., Бессмельцев, С. С., Chechetkin, A. V., & Грицаев, С. В. (2018) · Clinical oncohematology · doi:10.21320/2500-2139-2018-11-2-192-197 · Cited by 6
Sinitsyn, Y., Malone, A. K., Mandeli, J., Grosskreutz, C. L., Osman, K., Scigliano, E., Shi, P. A., & Isola, L. M. (2009) · Cytotherapy · doi:10.1080/14653240902849770 · Cited by 7
Diagnosis and Treatment of Multiple Myeloma
Rajkumar, S. V., & Kyle, R. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_33 · Cited by 6
Self-citationPark, S., Shin, S.-H., Lee, J., Jeon, Y., Yahng, S., & Min, C. (2023) · Cancers · doi:10.3390/cancers15194783 · Cited by 5
“Furthermore, concerns have been raised that CD34+ stem cells may be impaired by daratumumab and/or lenalidomide-containing induction [20,33,34].”
BackgroundTang, H. K. K., Fung, C. Y., Hwang, Y., Lee, H., Lau, G. S. N., Yip, S. F., Kho, B., Lau, C. K., Leung, K. H., Au, E. Y. L., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02227-0 · Cited by 7
Khan, S., Bergstrom, D. J., Côté, J. A., Kotb, R. R., LeBlanc, R., Louzada, M., Mian, H. S., Othman, I., Colasurdo, G., & Visram, A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.012 · Cited by 6
Moosig, F., Reinhold‐Keller, E., Holl‐Ulrich, K., Feller, A. C., Bley, T. A., Holle, J. U., Zwerina, J., Lamprecht, P., Dalhoff, K., Venhoff, N., et al. (2012) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-012-0988-6 · Cited by 7
Afable, M. G., Caimi, P. F., Hosing, C. M., Lima, M. J. G. D., Khouri, I. F., William, B. M., Nieto, Y. L., Cooper, B., Anderlini, P. N., Gerson, S. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.022 · Cited by 5
“Specific antineoplastic agents, including lenalidomide [7,8], fludarabine [9,10], and melphalan [11], have been associated with poor mobilization rates.”
Mobilization of Peripheral Blood Hematopoietic Cells for Autologous HCT
Shea, T. C., & DiPersio, J. F. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch40 · Cited by 7
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
Sidana, S., Tandon, N., Gertz, M. A., Dispenzieri, A. A., Buadi, F. K., Lacy, M. Q., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/s41409-017-0020-5 · Cited by 5
Self-citationPompa, A., Pettine, L., Giannarelli, D., París, L., Torretta, L., Cavallaro, F., Levati, G. V., Stefanoni, P., Mocellin, C., Galli, M., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13693 · Cited by 5
Mobilisation des cellules souches hématopoïétiques : état de l’art en 2011 et perspectives
Bijou, F. D., Ivanović, Z., Boiron, J.-M., & Nicolini, F. E. (2011) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2011.02.028 · Cited by 5
Pelus, L. M., & Farag, S. S. (2011) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s6713 · Cited by 7
“The risk of mobilization failure is also related to the duration of prior treatment with l enalidomide.(44) The failure to mobilize sufficient CD34+ cells after lenalidomide, however, may be largely overcome by mobilization using chemotherapy plus G-CSF.”
Sarıcı, A., Erkurt, M. A., Bahçecíoğlu, Ö. F., Gök, S., Kuku, İ., Biçim, S., Berber, İ., Kaya, E., & Özgül, M. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103159 · Cited by 5
Uzoka, C. C., Liu, L. C., Park, Y. M., Lin, Y., Patel, P. R., Campbell‐Lee, S. A., Sweiss, K. I., Wang, X., Tepak, E., Peace, D. J., et al. (2021) · Journal of Clinical Apheresis · doi:10.1002/jca.21914 · Cited by 5
“Lenalidomide, commonly used to treat MM patients as an induction agent with known myelotoxic effects, has been shown to negatively impact HSPC mobilization.(26-29) Despite receiving myelotoxic therapy prior to HSPC mobilization, the autologous MM donor group rendered the highest mobilization response in comparison to…”
BackgroundLenalidomide in multiple myeloma
Sirohi, B., & Powles, R. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.123 · Cited by 5
Crusoé, E. D. Q., Higashi, F., Martınez, G., Barros, J. C., Bellesso, M., Rossato, M., Marret, A. C. G., CHIATTONE, C. S., & Hungria, V. (2016) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2016.06.004 · Cited by 6
AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA
Harousseau, J. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.008 · Cited by 5
Controversies in Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma
Bhatnagar, B., & Ashraf, Z. (2013) · InTech eBooks · doi:10.5772/54115 · Cited by 4
Miyamoto‐Nagai, Y., Mimura, N., Tsukada, N., Aotsuka, N., Ri, M., Katsuoka, Y., Wakayama, T., Suzuki, R., Harazaki, Y., Matsumoto, M., et al. (2022) · eJHaem · doi:10.1002/jha2.534 · Cited by 4
Li, K., Shuping, S., Chang, S., Yiyue, C., Qinyu, X., Zhang, T., & Wu, B. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2389 · Cited by 5
“37,38 However, further research is needed to fully elucidate this process.”
BackgroundHigh-risk smoldering myeloma: Perspective on watchful monitoring
Leng, S., & Lentzsch, S. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.001 · Cited by 4
Yoshifuji, K., Toya, T., Adachi, H., Fujita, M., Wada, A., Konuma, R., Kishida, Y., Konishi, T., Nagata, A., Yamada, Y., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02622-0 · Cited by 5
Kriegsmann, K., & Wuchter, P. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9574-5_4 · Cited by 5
Sauer, S., Pavel, P., Schmitt, A., Cremer, M., Kriegsmann, M., Bruckner, T. M., Jordan, K., Wuchter, P., Müller‐Tidow, C., & Kriegsmann, K. (2020) · BMC Cancer · doi:10.1186/s12885-020-06873-7 · Cited by 5
Lin, C., & Sung, Y. (2009) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(09)50006-4 · Cited by 4
Madan, S., & Kumar, S. K. (2011) · Therapy · doi:10.2217/thy.11.39 · Cited by 5
Self-citationFigueiredo, A., Kassis, R., Albacker, R., McCurdy, A. B. R., Kekre, N. K., & Atkins, H. L. (2019) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2019.03.005 · Cited by 5
“Mobilization regimen, n (%) (GCSF) granulocyte colony stimulating factor alone 6 (9) – – – 6 (1.”
BackgroundMultiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Self-citationYoshihara, S., Yoshihara, K., Shimizu, Y., Imado, T., Takatsuka, H., Kawamoto, H., Misawa, M., Ifuku, H., Ohe, Y., Okada, M., et al. (2021) · Hematology · doi:10.1080/16078454.2021.1926101 · Cited by 3
“several retrospective studies showed that a longer exposure to lenalidomide has a negative impact on a stem cell yield [8,9].”
BackgroundHe, D., Zhu, C., Guo, X. Z., Huang, X., Han, X., Zheng, G., Zhao, Y., Yang, Y., Wu, W., Ge, J., et al. (2022) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2022.103618 · Cited by 3
Chandler, T., Parrish, C., Καρακάντζα, Μ., Carmichael, J., Pawson, D., Cook, G., & Seymour, F. (2023) · eJHaem · doi:10.1002/jha2.702 · Cited by 3
Siddiqui, M. A., & Gertz, M. A. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802084972 · Cited by 3
“004) to collect sufficient number of CD34þ cells for HDT compared to patients treated with dexamethasone, thal/dex, or VAD as induction chemotherapy [51].”
MethodSelf-citationInitial therapy in multiple myeloma: investigating the new treatment paradigm
Kettle, J. K., Finkbiner, K., Klenke, S. E., Baker, R. D., Henry, D., & Williams, C. B. (2009) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155208101096 · Cited by 3
Functional Cure as a New Concept of Therapy for Multiple Myeloma
Семочкин, С. В. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-2-105-120 · Cited by 3
Rallon, T., Moine-Picard, C., Dedier, M., Mebarki, M., Faivre, L., Cornu, S., Deniaux, M., Robert, I., Larghero, J., Cras, A., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.102037 · Cited by 2
Tufail, M., Siegel, D. S. D., McBride, L., Bilotti, E., Bello, E., Anand, P., Olivo, K., Bendarz, U., McNeill, A., & Vesole, D. H. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.01.004 · Cited by 2
Ardakani, M. T., Ahadi, H. R., Bonakchi, H., Parkhideh, S., Tavakoli, F., Moshari, M. R., Soleimani, M., & Hajifathali, A. (2022) · International Journal of Cancer Management · doi:10.5812/ijcm-120241 · Cited by 2
Wolf, J., Seymour, F., Parrish, C., Chandler, T., Holt, M., Griffin, J., & Καρακάντζα, Μ. (2025) · Journal of Clinical Apheresis · doi:10.1002/jca.70012 · Cited by 4
Annual clinical updates in hematological malignancies: a continuing medical education series
(2017) · American Journal of Hematology · doi:10.1002/ajh.24907 · Cited by 3
Novel Induction Regimens in Multiple Myeloma
Runcie, K. D., & Mark, T. M. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0282-1 · Cited by 2
Induction Therapy in Multiple Myeloma
Mine, S., & Beksaç, M. (2013) · InTech eBooks · doi:10.5772/55151 · Cited by 2
“…can cause myelosuppression and concerns have been raised that its use may negatively impact the ability to mobilize stem cells in patients who received lenalidomide as part of their induction therapies (Kumar et al., 2007; Mazumder et al., 2008; Paripati et al., 2008; Popat et al., 2009).”
BackgroundLupo, B., & Palumbo, A. (2012) · Advances in Hematology · doi:10.1155/2012/906247 · Cited by 3
Fung, H. C. H., Nathan, S., & Maciejewski, J. (2010) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s6258 · Cited by 2
Controversies in Multiple Myeloma: to Transplant or Not?
Preeshagul, I. R., van Besien, K., & Mark, T. M. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0230-5 · Cited by 2
Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
Fawole, A. A., Abonour, R., Stender, M., Shatavi, S. V., Gaikazian, S. S., Anderson, J., & Jaiyesimi, I. A. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.897702 · Cited by 2
Jain, A. (2020) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-020-01273-0 · Cited by 2
Swan, D., Henderson, R. B., McEllistrim, C., Naicker, S. D., Quinn, J., Cahill, M. R., Mykytiv, V., Lenihan, E., Mulvaney, E., Nolan, M., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.011 · Cited by 2
Banday, S. Z., Guru, F. R., Ayub, M., Ahmed, S. N., Banday, A. Z., Mir, M. H., Nisar, R., Hussain, S., Bhat, G. M., & Aziz, S. A. (2023) · Cureus · doi:10.7759/cureus.36642 · Cited by 3
Röhnert, M. A., Seifert, A., Trautmann‐Grill, K., Röllig, C., Zimmer, K., Egger‐Heidrich, K., Bill, M., Heberling, L., Schulze, F., Blechschmidt, M., et al. (2026) · Transfusion · doi:10.1111/trf.70165 · Cited by 1
Agarwal, R., & Abidi, M. H. (2012) · Hematology Reports · doi:10.4081/hr.2012.e26 · Cited by 1
Autologous stem cell transplantation for multiple myeloma: history and future
Shimazaki, C. (2013) · Cited by 4
Бессмельцев, С. С. (2013) · Clinical oncohematology · doi:10.21320/2500-2139-2013-6-4-379-414 · Cited by 7
Cai, H., Bai, J., Li, J., Cai, H., Duan, M., Cao, X., Chen, M., Zhou, D., & Zhang, W. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.63353 · Cited by 2
Kostroma, I. I., Zherniakova, A., Chubukina, Z. V., Semenova, N. Y., Запреева, И. М., Тиранова, С. А., Бессмельцев, С. С., Чечеткин, А. В., & Грицаев, С. В. (2019) · Clinical oncohematology · doi:10.21320/2500-2139-2019-12-1-32-36 · Cited by 1
Öztürk, C., Topçuoğlu, P., Dalva, K., İlhan, O., & Özcan, M. (2018) · LLM Dergi · doi:10.5578/llm.67552 · Cited by 1
“Bone Marrow Transplant 2001;27(8):837.”
BackgroundVTD in comparison with VCD does not affect stem cell yields with G-CSF only mobilization
Škerget, M., Skopec, B., & Sever, M. (2020) · Acta Haematologica Polonica · doi:10.2478/ahp-2020-0009 · Cited by 2
Metadata
- Authors
- Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., & Gertz, M. A.
- Affiliations
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Kumar, S
- ORCID
- Venue
- Leukemia
- Published
- 2007-06-21
- Volume
- 21
- Issue
- 9
- Pages
- 2035-2042
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2036985459
- Semantic Scholar
- 831eb40600d3fcbfc29f2b9cc655e7c78f420e1f
- Cited by
- 351
- References
- 35
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 16 · 2018: 9 · 2017: 17 · 2016: 15 · 2015: 23 · 2014: 15 · 2013: 29 · 2012: 27
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- lenalidomide, peripheral blood stem cell mobilization, stem cell engraftment, multiple myeloma, newly diagnosed multiple myeloma, granulocyte colony-stimulating factor, CD34+ cell yield, apheresis, VAD chemotherapy, bortezomib, mobilization failure
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Vincristine, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Hormonal, Hematopoietic Stem Cell Mobilization, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.